ArticleFrontiers in pharmacology2026
Shu Gan Jie Yu herbal combination enhances tamoxifen sensitivity in breast cancer cells via modulation of the SNCG/
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the therapeutic effects and potential mechanisms of Methods: The water extract of the CCR was tested on MCF-7, T47D cell lines, and their SNCG-overexpressing counterparts. The CCK8 assay was used to evaluate the effects of CCR, TAM alone, and their combined application. CompuSyn and SynergyFinder software were employed to assess whether the combination therapy exhibited synergistic effects. Colony formation assays and flow cytometry were conducted to examine the impact on proliferation and apoptosis of SNCG-overexpressing cells, respectively. Co-immunoprecipitation (CoIP) and dual-luciferase reporter gene assays were used to investigate the interaction between SNCG and ERα. Western blot analysis was performed to evaluate the effects of CCR and TAM, alone or in combination, on the expression of ERα, SNCG, and phosphorylated proteins in MCF-7 and T47D cells, as well as on the expression of ERα, SNCG, EGFR, AKT, mTOR, MAPK, ERK and their phosphorylated forms in SNCG-overexpressing cells. Results: In our study, treatment with CCR enhanced the inhibitory effects of TAM on the breast cancer cell lines examined. CoIP and dual-luciferase reporter gene assays indicated a potential protein-protein interaction between SNCG and ERα, suggesting that SNCG overexpression enhanced ERα promoter activity. Overexpression of SNCG led to the upregulation of ERα. CCR combined with TAM markedly suppressed cell migration and colony formation, and significantly induced apoptosis. These effects were mechanistically associated with reduced protein expression levels of SNCG, Conclusion: Our results indicate that CCR exhibits potent anti-proliferative activity against ER + breast cancer. Moreover, the combination of CCR and TAM synergistically enhances the anti-proliferative activity, at least in part via modulation of the SNCG/
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.